DNLI250117C45000
- 0.00
- 0.000.00%
Denali Therapeutics Newsroom
Denali Therapeutics Is Maintained at Overweight by JP Morgan
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $30
BofA Trims Denali Therapeutics Price Target to $30, Says Weakness an Opportunity
Stifel Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $37
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $24
Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its...
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
Denali Therapeutics Price Target Lowered to $32 From $35 at BTIG
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87
Denali Therapeutics (DNLI) Gets a Buy From J.P. Morgan
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Denali Therapeutics Initiated at Outperform by Baird
Denali Therapeutics Analyst Ratings
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More -- Barrons.com
Biggest Stock Movers Tuesday: NARI, DNLI, and More
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Express News | Denali Therapeutics Inc : JP Morgan Cuts Target Price to $24 From $28
Denali Therapeutics Maintains Strong Buy Rating Amid Setbacks, Fueled by Promising BBB Platform